Peptide-mediated targeted delivery of SOX9 nanoparticles into astrocytes ameliorates ischemic brain injury
Hyo Jung Shin, Seung Gyu Choi, Fengrui Qu, Min‐Hee Yi, Choong‐Hyun Lee, Sang Ryong Kim, Hyeong-Geug Kim, Jaewon Beom, Yoon Young Yi, Do Kyung Kim, Eun-hye Joe, Hee‐Jung Song, Yonghyun Kim, Dong Woon Kim
Abstract
-glycolic acid (PLGA) nanoparticle plasmid delivery system in a photothrombotic stroke animal model. We designed PLGA nanoparticles to exclusively enhance SOX9 gene expression in glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes. Our observations indicate that PLGA nanoparticles encapsulated with GFAP:SOX9:tdTOM reduce ischemia-induced neurological deficits and infarct volume through the prostaglandin D2 pathway. Thus, the astrocyte-targeting PLGA nanoparticle plasmid delivery system provides a potential opportunity for stroke treatment. Since the only effective treatment currently available is reinstating the blood supply, cell-specific gene therapy using PLGA nanoparticles will open a new therapeutic paradigm for brain injury patients in the future.